ArticlePloS one2026
A cross-border seroprevalence study on HBV, HCV, HDV and HIV in remote Amazonian communities on the border between French Guiana and Suriname.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNational epidemiological data are essential to achieve viral hepatitis elimination goals. However, viral hepatitis and HIV epidemiology in French Guiana (FG) and Suriname is mainly limited to urban areas. We therefore assessed the prevalence, associated determinants, and knowledge, attitudes, practices, and beliefs (KAP-B) regarding hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and HIV in the isolated area of the Maroni River, bordering FG and Suriname.
methodsBetween January 2018 and February 2019, adults (≥18 years) living along the Maroni were enrolled in this cross-sectional study and completed a risk factor and KAP-B questionnaire. Participants were tested for viral hepatitis and HIV using serological and molecular analyses: HBV (HBsAg, anti-HBcore antibodies, anti-HBs, HBV DNA), HCV (HCV-antibodies, HCV RNA), HDV (HDV-antibodies), and HIV (HIV-antibodies/antigen, HIV RNA). Age- and sex-adjusted HBV, HCV, and HIV prevalences were estimated using post-stratification weighting.
findingsAmong 2286 participants, adjusted prevalences were respectively 2.08% (95%CI: 1.49-2.66; n = 46) for HBsAg, 25.6%, (95%CI: 20.89-29.24, n = 646) for resolved HBV infection (negative HBsAg and positive anti-HBcore antibodies), 0.13% (95%CI: 0.0-0.27; n = 5) for HCV-antibodies, and 0.65% (95%CI: 0.0-1.40; n = 12) for HIV-antibodies. There were no HDV infections. HBV exposure (acute or resolved) was independently associated with age (per 10-year increase aOR:1.27, 95%CI: 1.18-1.37, p < 0.0001), males (aOR:1.34, 95%CI: 1.10-1.65, p = 0.006), Maroon (aOR:2.22, 95%CI: 1.27-4.06) or other ethnic groups (aOR:2.94, 95%CI: 1.61-5.59) versus Amerindians, (p = 0.002), and higher education (aOR:0.71, 95%CI: 0.56-0.90, p = 0.005). Older age (per 10-years increase aOR:1.64, 95%CI: 1.11-2.44), p = 0.01) and non-autochthonous origin (aOR:3.81, 95%CI: 1.14-12.26, p = 0.02) were associated with HIV. Less than one in six participants correctly identified viral hepatitis transmission modes.
conclusionHBV, HCV and HIV prevalences along the Maroni River were comparable to urban areas and remain concerning. Knowledge about viral hepatitis was low. Achieving viral hepatitis elimination goals requires awareness campaigns and test-and-treat strategies tailored to hard-to-serve populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.